A patient information brochure for momelotinib (OMJJARA) has been prepared by the sponsor, and is available from the TGA (Therapeutic Goods Administration) website.
It is titled OMJJARA momelotinib – Consumer Medicine Information and is available HERE.
Please note that as this medicine has been specifically developed for myeloproliferative neoplasms, the MPN AA has not prepared a dedicated treatment brochure.
We have however, prepared a more generic brochure, What can I do to help myself if I have an MPN.
You may wish to download this in conjunction with the OMJJARA Consumer Medicine Information linked above.
Articles on Momelotinib
Post-FDA Approval Experience With Momelotinib in JAK Inhibitor-Naïve Myelofibrosis: Focus on Anemia Response and Treatment-Emergent Nephropathy and Peripheral Neuropathy, Correspondence, American Journal of Hematology (FREE ACCESS)
